doi: 10.1007/978-3-7091-9113-2_52.
Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat
Affiliations
- PMID: 2128510
- DOI: 10.1007/978-3-7091-9113-2_52
Item in Clipboard
Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat
J Neural Transm Suppl.
1990.
Abstract
Methods potentially suitable for the determination of the COMT inhibitory properties of CGP 28014 (N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine) in humans were tested in rats: the measurement of effects on HVA levels and on the conversion of exogenously administered L-DOPA into its O-methylated derivative, in serum and striatum. The compound decreased HVA as well as the conversion of L-DOPA to O-methyl-DOPA similarly in serum and striatum. The latter parameter was considered to be more useful for the assessment of COMT inhibition in humans, because it is less affected by diurnal changes, dietary effects, physical activity etc.
Similar articles
-
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.Br J Pharmacol. 1992 Mar;105(3):569-74. doi: 10.1111/j.1476-5381.1992.tb09020.x. Br J Pharmacol. 1992. PMID: 1628144 Free PMC article.
-
CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11. doi: 10.1007/BF00169442. Naunyn Schmiedebergs Arch Pharmacol. 1990. PMID: 1980718
-
Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.Br J Pharmacol. 1994 May;112(1):13-8. doi: 10.1111/j.1476-5381.1994.tb13021.x. Br J Pharmacol. 1994. PMID: 7518301 Free PMC article.
-
BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.Eur J Pharmacol. 2001 May 18;420(1):27-32. doi: 10.1016/s0014-2999(01)01020-2. Eur J Pharmacol. 2001. PMID: 11412836
-
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.Gen Pharmacol. 1994 Sep;25(5):813-24. doi: 10.1016/0306-3623(94)90082-5. Gen Pharmacol. 1994. PMID: 7835624 Review.
Cited by
-
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.CNS Drug Rev. 2007 Fall;13(3):352-79. doi: 10.1111/j.1527-3458.2007.00020.x. CNS Drug Rev. 2007. PMID: 17894650 Free PMC article. Review.
-
Clinical pharmacology of the new COMT inhibitor CGP 28,014.Neurochem Res. 1993 Nov;18(11):1163-7. doi: 10.1007/BF00978368. Neurochem Res. 1993. PMID: 8255368
-
COMT inhibitors and metabolism of fluorodopa enantiomers in aggregating cell cultures.Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):582-5. doi: 10.1007/BF00167233. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8133902
-
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.Br J Pharmacol. 1992 Mar;105(3):569-74. doi: 10.1111/j.1476-5381.1992.tb09020.x. Br J Pharmacol. 1992. PMID: 1628144 Free PMC article.
-
Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.CNS Drugs. 1994 Mar;1(3):172-9. doi: 10.2165/00023210-199401030-00002. CNS Drugs. 1994. PMID: 27520516
MeSH terms
Substances
LinkOut - more resources
Miscellaneous